# Gene Solutions Hosts K-CONNECT Summit 2026, Uniting Oncology Experts Across Asia-Pacific

- Link: https://www.thailand-business-news.com/pr-news/gene-solutions-hosts-k-connect-summit-2026-uniting-oncology-experts-across-asia-pacific
- Published: 2026-06-18T16:28:00+07:00
- Author: PR Newswire

DA NANG, Vietnam, June 18, 2026 /PRNewswire/ — [**Gene Solutions**](https://genesolutions.com/)
announced the successful conclusion of [**K-CONNECT Summit 2026**](https://kconnect.genesolutions.com/event/k-connect-summit-2026/),
a regional scientific forum that brought together leading oncology experts, clinicians,
researchers and healthcare stakeholders to discuss how **Artificial Intelligence(
AI)** and **multi-omics** are reshaping cancer care across Asia-Pacific.

[[

Held in **Da Nang, Vietnam**, the hybrid summit attracted **more than 250 onsite
regional oncology experts**, with **over 1,000 online participants**. Under the 
theme **"AI & Multi-omics: Shifting Paradigms in the New Era of Early Cancer Detection
and Precision Oncology,"** the program explored how multi-omics — the integration
of genomic, epigenomic, transcriptomic and fragmentomic data — can advance earlier
cancer detection, more comprehensive molecular profiling, longitudinal disease monitoring
and highly personalized treatment decisions.

**Prof. Herbert Ho Fung Loong**, Co-chair of the K-CONNECT Summit 2026 and Clinical
Associate Professor, Department of Clinical Oncology, The Chinese University of 
Hong Kong, stated:

"Cancer care across Asia-Pacific is at a critical inflection point. As cancer incidence
continues to rise, the ability to detect cancer earlier, more treatable stages and
deliver more precise treatment is essential to improving outcomes and reducing the
burden on patients, families and healthcare systems. AI-powered multi-omics liquid
biopsy technologies — represent a transformative advance, with potential to enable
broader access to earlier detection and truly personalized cancer care, when supported
by robust clinical evidence, local implementation pathways and multidisciplinary
collaboration."

**Assoc. Prof. Do Anh Tu**, Co-chair of K-CONNECT Summit 2026 and Vice Director 
of Vietnam National Cancer Hospital (K Hospital) added: "The K-CONNECT Summit 2026
demonstrated the value of regional collaboration in advancing the next era of oncology.
Bringing together clinicians, scientists and healthcare leaders across Asia-Pacific
is essential as it enables us to learn from each other while moving from single-
modality approaches toward integrated, AI-enabled and multi-omics-driven cancer 
care. The future will depend not only on technological innovation, but also on rigorous
evidence generation, regional collaborations, responsible implementation and locally
relevant care pathways."

[[

Speakers included **Prof. David CL Lam** of The University of Hong Kong, **Prof.
Sumei Cao** of Sun Yat-sen University Cancer Center, **Dr. Le Son Tran** of Gene
Solutions, **Prof. Herbert Ho Fung Loong** of The Chinese University of Hong Kong,**
Dr. Vaibhav Choudhary** of Nanavati Max Super Specialty Hospital, **Dr. Lan Tu Ngoc
Ly** of Gene Solutions, **Assoc. Prof. Vu Le Thuong** of University Medical Center
Ho Chi Minh City, **Assoc. Prof. Huy Trinh Le** of Hanoi Medical University, **Asst.
Prof. Lucksamon Thamlikitkul** of Siriraj Hospital, **Dr. Basma M’Barek **of Franco-
Vietnamese Hospital, **Dr. Tom Wei-Wu Chen** of National Taiwan University Hospital
and **Dr. Nguyen Duy Sinh** of Gene Solutions, with panel contributions from leading
clinicians across Vietnam, Malaysia, Thailand, Taiwan region and Hong Kong SAR.

**Advancing Multi-Cancer Early Detection**

The first session focused on **multi-cancer early detection (MCED)**, a screening
approach designed to detect cancer-associated signals from multiple cancer types,
often from a single blood draw. Speakers discussed how **circulating tumor DNA (
ctDNA)** — tumor-derived DNA fragments released into the bloodstream — can be analyzed
with AI and multi-omics to complement existing screening programs, particularly 
for cancers that lack established screening pathways.

**Prof. David CL Lam** addressed the ”grey zone” in lung cancer screening with LDCT
and the complementary role of ctDNA and multi-omics; **Prof. Sumei Cao** shared 
risk-stratified screening experience from Southern China while **Dr. Le Son Tran**
presented clinical evidence for SPOT-MAS, Gene Solutions’ AI-powered multi-cancer
screening platform, which recently received U.S FDA Breakthrough Device Designation.**
Prof. Herbert Ho Fung Loong** further emphasized the health-economic value of earlier
detection and the potential of blood-based screening as an accessible option to 
complement current standard of care and improve patient outcomes. The panel discussed
technical challenges, real-world evidence, population selection and the positioning
of MCED as a complement — not a replacement — to guideline-recommended screening
strategies.

**From Molecular Profiling to Real-Time Monitoring**

The second session explored **comprehensive genomic and transcriptomic profiling(
CGTP)** with integrated ctDNA-based monitoring. CGTP combines DNA and RNA analysis
to identify clinically relevant cancer alterations, including mutations, gene fusions
and expression patterns that may help to guide treatment selection. The session 
also addressed **molecular residual disease (MRD)**, defined as molecular evidence
of residual cancer that may persist after treatment even when not detectable on 
imaging.

**Dr. Vaibhav Choudhary** described how liquid biopsy is moving from feasibility
toward clinical consequence; **Dr. Lan Tu Ngoc Ly** discussed how K-TRACK and K-
4CARE integrate DNA, RNA and ctDNA features to support treatment decision-making;**
Assoc. Prof. Vu Le Thuong** showed how tissue and plasma profiling can support lung
cancer management; and **Assoc. Prof. Huy Trinh Le** demonstrated the role of profiling
and ctDNA in gastrointestinal cancers. The panel addressed cost, reimbursement, 
turnaround time, validation, standardization and interpretation of discordant tissue
and plasma findings.

**Defining the Future of Precision Oncology**

The third session focused on translating molecular insights into actionable clinical
decisions across diverse tumor types. **Asst. Prof. Lucksamon Thamlikitkul** underscored
that precision oncology hinges on meticulous patient selection, judicious choice
of diagnostic tests, and the expert interpretation of results within the full clinical
context. **Dr. Basma M’Barek** presented compelling ctDNA-guided monitoring in breast
cancer, with a particular focus on the detection of ESR1-mediated resistance. **
Dr. Tom Wei-Wu Chen** shared valuable insights from soft tissue sarcoma cases and
the MELODY study, highlighting the planned use of Gene Solutions’ **K-4CARE MAX**
platform for profiling and ctDNA-based monitoring in a rare-cancer clinical research
setting.

**Dr. Nguyen Duy Sinh** outlined a forward-looking direction centered on deeper 
multi-omics integration, including DNA and RNA analysis, immunotherapy response 
prediction, tumor microenvironment assessment and functional precision medicine.
He emphasized the potential role of **K-4CARE MAX** in predicting neo-antigen expression
and tumor microenvironment factors relevant to immunotherapy and cancer vaccine 
strategies, as well as the utility of 3D organoid models for evaluating tumor response
to therapies.

Explore full details of each scientific section [HERE](https://genesolutions.com/news/best-of-k%E2%80%91connect-summit-2026-translating-multi-omics-and-ai-into-real-world-precision-oncology/)

Following the success of K-CONNECT Summit 2026, Gene Solutions will continue expanding
the K-CONNECT platform through scientific education, expert exchange, clinical evidence
sharing and strategic partnerships focused on improving equitable access to advanced
genomic solutions worldwide.

**About Gene Solutions**

**Gene Solutions** is a global biotechnology company headquartered in Singapore 
with a mission to make advanced genomic solutions accessible and affordable. Leveraging
next-generation sequencing, multi-omics and artificial intelligence, the company
offers a portfolio of solutions across multi-cancer detection, precision oncology
and reproductive health, including [**SPOT-MAS**](https://spotmas.com/), [**K-TRACK**](https://genesolutions.com/our-test/k-track)
and [**K-4CARE**](https://genesolutions.com/our-test/k-4care).

Gene Solutions operates CAP-accredited NGS laboratories and has delivered millions
of genetic tests worldwide since 2017. For more information, visit [**www.genesolutions.com**](https://www.genesolutions.com/)
and follow Gene Solutions on [**LinkedIn**](https://www.linkedin.com/company/genesolutions)**,**
[**Facebook**](https://www.facebook.com/GeneSolutions.Global/)**, **and [**X (Twitter)**](https://x.com/GS_bio).

For inquiries, please contact [pr@genesolutions.com](https://www.thailand-business-news.com/pr-news/pr@genesolutions.com)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Gene Solutions Hosts K-CONNECT Summit 2026, Uniting Oncology Experts Across Asia-Pacific ](http://www.prnasia.com/story/archive/4983492_AE83492_0?rand=184833)
